<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Resistance of &lt;i&gt;Streptococcus pneumoniae&lt;/i&gt; to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Resistance of <i>Streptococcus pneumoniae</i> to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Resistance of <i>Streptococcus pneumoniae</i> to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel M Musher, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas M File, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Streptococcus pneumoniae</em> (pneumococcus) is among the most commonly identified bacterial causes of upper and lower respiratory tract infections including pneumonia, otitis media, acute rhinosinusitis, and acute exacerbations of chronic obstruction pulmonary disease (COPD). However, rates of pneumococcal infections are overall declining, largely due to widespread use of pneumococcal conjugate vaccination in children and adults [<a href="#rid1">1,2</a>].</p><p>Penicillin (or <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> because of more reliable absorption after oral administration and a much longer half-life) remains the drug of choice for treating susceptible pneumococcal infection. In this section, alternative drugs will be discussed. </p><p>The fluoroquinolones (often called quinolones) have been used widely to treat adults with these conditions. In 2016, the US Food and Drug Administration stated that the serious adverse effects associated with fluoroquinolones generally outweigh the benefits for patients with acute rhinosinusitis (as well as acute bronchitis and uncomplicated urinary tract infections) who have other treatment options [<a href="#rid3">3</a>]. This safety alert is likely to reduce the indiscriminate use of the fluoroquinolones, thereby preserving the susceptibility of pneumococci. (See  <a class="medical medical_review" href="/d/html/490.html" rel="external">"Fluoroquinolones", section on 'Benefits and risks of use'</a>.)</p><p><a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> is recommended as an alternative agent for empiric treatment of pneumonia in adult outpatients [<a href="#rid4">4</a>], acute exacerbation of COPD [<a href="#rid5">5</a>], and acute bacterial rhinosinusitis [<a href="#rid6">6</a>] and as an alternative agent for patients with penicillin allergy.</p><p><a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">Trimethoprim-sulfamethoxazole</a> (TMP-SMX) was commonly used to treat these conditions from the mid-1970s to the mid-1990s, but this combination drug has largely fallen out of favor because of the high rate of pneumococcal resistance.</p><p>Pneumococci were uniformly susceptible to all antibiotics used to treat respiratory tract bacterial infections until outbreaks of infection due to antibiotic-resistant pneumococci occurred in South Africa in the late 1970s [<a href="#rid7">7,8</a>]. Although the responsible organisms were called penicillin-resistant pneumococci, they had acquired genetic material that encoded broad resistance both to penicillin and to other commonly used antibiotics. In the ensuing decades, pneumococcal resistance has arisen in a number of clinically relevant classes of antibiotics.</p><p>The mechanisms of resistance and the prevalence of resistance to the fluoroquinolones, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, and TMP-SMX are reviewed here. Resistance to the other classes of drugs is discussed separately. (See  <a class="medical medical_review" href="/d/html/7034.html" rel="external">"Resistance of <i>Streptococcus pneumoniae</i> to beta-lactam antibiotics"</a> and  <a class="medical medical_review" href="/d/html/7033.html" rel="external">"Resistance of <i>Streptococcus pneumoniae</i> to the macrolides, azalides, and lincosamides"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">FLUOROQUINOLONES</span><span class="headingEndMark"> — </span>The fluoroquinolones consist of a family of related compounds, including <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>, <a class="drug drug_general" data-topicid="8760" href="/d/drug information/8760.html" rel="external">gemifloxacin</a>, <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a>, <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a>, and <a class="drug drug_general" data-topicid="9715" href="/d/drug information/9715.html" rel="external">ofloxacin</a>. Use of these drugs to treat respiratory infection represented a major therapeutic advance. At the time of their introduction, these drugs were uniformly active against <em>S. pneumoniae</em> as well as <em>Haemophilus</em>, <em>Moraxella</em>, <em>Legionella</em>, <em>Mycoplasma</em>, and <em>Chlamydia </em>spp. Except for very low rates of resistance of pneumococci (not exceeding 1 to 2 percent of isolates in the United States) and rare reports of resistance among <em>Haemophilus</em>, they remain so to the present. (See  <a class="medical medical_review" href="/d/html/490.html" rel="external">"Fluoroquinolones"</a>.)</p><p>The term "respiratory fluoroquinolone" has been applied to <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a>, <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a>, and <a class="drug drug_general" data-topicid="8760" href="/d/drug information/8760.html" rel="external">gemifloxacin</a> based on their very low minimum inhibitory concentrations (MICs) for <em>S. pneumoniae</em> and other respiratory pathogens and achievable drug levels. They exhibit increased potency relative to <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> and <a class="drug drug_general" data-topicid="9715" href="/d/drug information/9715.html" rel="external">ofloxacin</a> against <em>S. pneumoniae</em> [<a href="#rid9">9-11</a>]. Although there are remarkably few reports of treatment failures with ciprofloxacin in the United States, this drug is not regarded as a "respiratory fluoroquinolone" and, accordingly, is not recommended for treatment of respiratory infections by the Infectious Diseases Society of America or the American Thoracic Society [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Mechanisms of action and resistance</span><span class="headingEndMark"> — </span>The fluoroquinolones bind topoisomerases, enzymes that govern the twisting and knotting of double-stranded deoxyribonucleic acid (DNA). The principal enzymes involved are gyrase and topoisomerase IV, more specifically, two subunits of gyrase, <em>gyrA</em> and <em>gyrB</em>, and two subunits of topoisomerase IV, <em>parC</em> and <em>parE</em>. By binding these sites, fluoroquinolones block enzymatic activity such that bacterial replication cannot take place. The specific site of action of a quinolone is determined by the avidity with which it binds each enzyme [<a href="#rid12">12-14</a>]. For example, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> binds exclusively with topoisomerase IV; <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> binds more avidly with topoisomerase IV and also binds gyrase. <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">Moxifloxacin</a> reacts more strongly with gyrase. <a class="drug drug_general" data-topicid="8760" href="/d/drug information/8760.html" rel="external">Gemifloxacin</a> binds avidly with both.</p><p>Fluoroquinolone resistance in <em>S. pneumoniae</em> generally occurs when several mutations in <em>gyrA</em> or <em>parC </em>reduce binding of the drug to the site of activity [<a href="#rid15">15,16</a>]. Occasionally, mutations in <em>parE</em> are responsible. Resistance is stepwise; single mutations generally have little effect, but the more mutations that have occurred, the more resistant an organism is likely to be. In general, isolates with mutations in parC only are resistant to <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> but not to the other quinolones, whereas isolates with mutations in gyrA only and isolates with mutations in both parC and gyrA tend to be resistant to all fluoroquinolones [<a href="#rid15">15</a>]. Isolates with more than one mutation are more likely to remain susceptible to <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a> or <a class="drug drug_general" data-topicid="8760" href="/d/drug information/8760.html" rel="external">gemifloxacin</a> than to ciprofloxacin or <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> [<a href="#rid16">16</a>]. Many pneumococcal isolates that are still regarded as susceptible have already acquired one mutation, but the fear that widespread resistance might result has not yet materialized.</p><p class="headingAnchor" id="H4"><span class="h2">Prevalence of resistance</span><span class="headingEndMark"> — </span>Early surveillance studies showed that no more than 1 percent of <em>S. pneumoniae</em> isolates in the United States were resistant to <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a>, <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a>, or <a class="drug drug_general" data-topicid="8760" href="/d/drug information/8760.html" rel="external">gemifloxacin</a> [<a href="#rid17">17</a>]. This also appears to be true for so-called replacement strains that have emerged since the widespread use of the 7-valent pneumococcal conjugate vaccine (PCV7), such as serotypes 19A, 35B, and 11A [<a href="#rid18">18</a>]. Overall rates of resistance to levofloxacin among nasopharyngeal isolates in Buffalo, New York remained stable from 2010 to 2016 but, after an initial decline, increased to <a class="drug drug_general" data-topicid="9715" href="/d/drug information/9715.html" rel="external">ofloxacin</a> during that same time period [<a href="#rid19">19</a>]. The increase is small and is probably of no clinical significance, but the trend was a steady increase in resistance to ofloxacin during the time studied.  </p><p>Widespread use of any of the fluoroquinolones increases the risk for emergence of resistance [<a href="#rid20">20</a>]. In a report from Canada, the prevalence increased from 1.5 percent in 1993 to 1994 to 2.9 percent in 1997 to 1998 [<a href="#rid21">21</a>], paralleling the use of fluoroquinolones; as the usage of these drugs has been curbed, the rate of resistance appears to have fallen to &lt;2 percent [<a href="#rid22">22,23</a>]. There may be pockets of higher rates of resistance in settings in which there is excessive use of fluoroquinolones. A study in assisted living facilities, for example, found 6 percent of all colonizing pneumococci to exhibit resistance to fluoroquinolones [<a href="#rid20">20</a>]. A review summarized concepts about the relationships among proper fluoroquinolone use, inappropriate use, and pneumococcal resistance [<a href="#rid24">24</a>].</p><p>Higher rates of resistance have been noted in other countries. In Croatia [<a href="#rid25">25</a>] and Hong Kong [<a href="#rid26">26</a>], 4 to 13 percent of pneumococci were reported resistant to fluoroquinolones, and a study from Asia in 2009 and 2010 found up to 4 percent prevalence of resistance to newer fluoroquinolones [<a href="#rid27">27</a>]. Similarly, in Belgium, resistance of noninvasive isolates to <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> increased to about 3 percent and high-level resistance to <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> increased to 9 percent in 2013 [<a href="#rid28">28</a>]. Within countries that report increasing incidence of resistance, the proportion of resistant isolates is much higher among older subjects and patients with chronic lung disease [<a href="#rid26">26</a>]. In contrast, in countries where antimicrobial use is conservative, such as Germany, almost no resistance has been reported [<a href="#rid21">21</a>].</p><p>A prospective cohort study of 3339 patients with invasive pneumococcal infection between 1995 and 2002 identified apparent risk factors for the acquisition of fluoroquinolone-resistant pneumococcal strains [<a href="#rid24">24,29</a>]. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Previous fluoroquinolone use (odds ratio [OR] 12.1)</p><p class="bulletIndent1"><span class="glyph">●</span>Current residence in a nursing home (OR 12.9)</p><p class="bulletIndent1"><span class="glyph">●</span>Nosocomial acquisition of infection (OR 9.9)</p><p></p><p class="headingAnchor" id="H8"><span class="h1">DOXYCYCLINE AND MINOCYCLINE</span><span class="headingEndMark"> — </span>The tetracyclines were discovered in the 1940s and, along with <a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">chloramphenicol</a>, were the first broad-spectrum antibiotics. For a variety of reasons relating to efficacy against pneumococci, pharmacokinetics, toxicity, cost, and marketing, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> has become the <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> of choice. However, in 2015, the cost of doxycycline increased 50-fold, from about 6 cents to more than $3.00 per pill, whereas <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> remains at about 50 cents per pill. There appear to be no notable differences in the in vitro susceptibility of pneumococci to minocycline or doxycycline, with both drugs being more effective than tetracycline [<a href="#rid30">30</a>]. Resistance of pneumococci to doxycycline had exceeded 20 percent for several decades but, as of 2019, has fallen to 12.5 percent [<a href="#rid31">31</a>], probably reflecting lack of use in both pediatric and adult populations. These drugs are also effective against most isolates of <em>H. influenzae</em>, <em>Moraxella catarrhalis</em>, <em>Legionella</em>, <em>Mycoplasma</em>,<em> </em>and <em>Chlamydia </em>spp, explaining their potential usefulness as empiric therapy in community-acquired pneumonia (CAP) [<a href="#rid4">4</a>]. Glycylcyclines, such as <a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a>, regarded as advanced tetracyclines, have greater in vitro activity against pneumococci [<a href="#rid32">32</a>].</p><p>The literature is remarkable for a paucity of either in vitro or in vivo studies of the efficacy of <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> or <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> in treating pneumococcal (or any other) pneumonia; this paucity appears to reflect the economics of the medical marketplace more than it reflects interest in or potential efficacy of the drug. Pharmaceutical manufacturers, who support comparative studies of antibiotics, usually choose to compare experimental compounds with drugs that are currently in vogue in order to position them to compete for market share. Some potentially excellent antibiotics are simply not studied, and it can be very difficult to obtain data on them. This principle applies to drugs such as doxycycline, minocycline, and <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX) and includes studies in vitro or in vivo. Two investigator-initiated randomized controlled studies compared doxycycline with quinolones in CAP and found no difference in outcomes [<a href="#rid33">33,34</a>], but these studies were small, and only a fraction of patients had pneumococcal pneumonia. A meta-analysis supports the use of doxycycline in pneumonia of mild to moderate severity [<a href="#rid35">35</a>]. <a class="drug drug_general" data-topicid="119253" href="/d/drug information/119253.html" rel="external">Omadacycline</a>, a newly developed <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a>, is effective in vitro against virtually all pneumococci [<a href="#rid35">35</a>] and could be considered for treatment.</p><p class="headingAnchor" id="H10"><span class="h2">Mechanisms of action and resistance</span><span class="headingEndMark"> — </span>Tetracyclines inhibit protein synthesis by binding to the 30S ribosomal unit, specifically blocking the binding of aminoacyl transfer ribonucleic acid (RNA) to the mRNA-ribosome complex. Although regarded as bacteriostatic (which it is for <em>Staphylococcus aureus</em>), <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> is bactericidal for pneumococcus. Resistance is mediated by one or more proteins that bind the drug into vesicles that are then extruded from the bacterium [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Prevalence of resistance</span><span class="headingEndMark"> — </span>At the Boston City Hospital in the late 1960s, pneumococci were uniformly susceptible to <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, with a median minimum inhibitory concentration (MIC) of 0.39 mcg/mL (range 0.04 to 0.78 mcg/mL) [<a href="#rid37">37</a>]. Higher concentrations of <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> were required to inhibit pneumococci, but no isolates were resistant. Rare cases of infection due to tetracycline-resistant pneumococci were reported in the United States in the 1960s [<a href="#rid38">38</a>]. By that time, a small but measurable percentage of isolates were resistant in England [<a href="#rid39">39</a>] and Scandinavia [<a href="#rid40">40</a>]. By the mid-1970s, England had an overall rate of resistance of approximately 13 percent, with regional variation ranging from 2 to 32 percent [<a href="#rid41">41</a>].</p><p>By 2010, in the United States, approximately 25 percent of pneumococcal isolates were <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> resistant [<a href="#rid17">17</a>], with resistance to <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> or <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> at about 20 percent. Tetracycline resistance was substantially greater among penicillin-resistant isolates. Studies from the United States and Canada have shown nearly results identical, with 87.5 percent of pneumococcal isolates being susceptible to doxycycline [<a href="#rid23">23,31</a>]. These findings validate the recommendation of the American Thoracic Society/Infectious Diseases Society of America guidelines for the empiric use of doxycycline (or minocycline, depending upon cost and availability) for empiric treatment of mild to moderate severity CAP. Susceptibility varies greatly in other countries, so a recommendation to use doxycycline cannot be universalized, and the use of <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> or <a class="drug drug_general" data-topicid="8676" href="/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> for empiric therapy may still be preferable in many parts of the world. </p><p class="headingAnchor" id="H13"><span class="h1">TRIMETHOPRIM-SULFAMETHOXAZOLE</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">Trimethoprim-sulfamethoxazole</a> (TMP-SMX) was regarded as excellent therapy specifically for pneumococcal infection as well as more generally for otitis, sinusitis, and acute exacerbation of chronic bronchitis until the mid-1990s when it fell out of favor partially due to the increased prevalence of resistance of <em>S. pneumoniae</em> and partially to the development of alternative drugs, such as the newer macrolides and the fluoroquinolones.</p><p class="headingAnchor" id="H14"><span class="h2">Mechanisms of action and resistance</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10024" href="/d/drug information/10024.html" rel="external">Trimethoprim</a> and sulfamethoxazole block two separate steps in the synthesis of <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a>, a needed substrate for bacterial survival. Sulfamethoxazole displaces paraaminobenzoic acid, blocking biosynthesis of dihydrofolate [<a href="#rid42">42</a>]. Trimethoprim binds avidly to the active site of the bacterial enzyme that reduces dihydrofolate to tetrahydrofolate [<a href="#rid43">43</a>].</p><p>When TMP-SMX was released, it was touted as a drug to which bacteria would never become resistant because the mutation rate to each component is 1 in 10<sup>7</sup> and a double mutation would only occur in 1 of 10<sup>14</sup> organisms. This prediction proved to be wrong because mutant bacteria simply developed alternative bypass pathways for folate synthesis.</p><p class="headingAnchor" id="H15"><span class="h2">Activity and prevalence of resistance</span><span class="headingEndMark"> — </span>Resistance of <em>S. pneumoniae</em> to TMP-SMX had clearly been evolving during the 1980s, but it first became prominent in 1986 when a cluster of penicillin-resistant isolates in Brooklyn was also found to be resistant to TMP-SMX [<a href="#rid44">44</a>]. Two years later, 11 percent of adult carriers and 30 percent of children in a daycare center in North Carolina who were carrying pneumococcus harbored TMP-SMX-resistant isolates [<a href="#rid45">45</a>]. Continued spread and selection of resistance was probably enhanced in children by the extensive use of this combination drug to treat otitis media [<a href="#rid45">45</a>] and in adults by the prophylactic use of TMP-SMX in acquired immunodeficiency syndrome (AIDS) patients [<a href="#rid46">46</a>].</p><p>Approximately one-third of all pneumococcal strains in the United States are resistant to TMP-SMX [<a href="#rid18">18</a>], ranging from 25 percent in the Northeast to 45 percent in the Southeast [<a href="#rid47">47,48</a>]. The prospective cohort study of 3339 patients with invasive pneumococcal infection cited above identified apparent risk factors for the acquisition of TMP-SMX-resistant pneumococcal strains [<a href="#rid49">49</a>]. These include previous use of TMP-SMX (odds ratio [OR] 4.7), <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> (OR 3.5), and penicillin (OR 1.7). In many other countries, rates of resistance are even higher, approaching 80 percent in some southeastern Asian countries.</p><p>With the widespread use of the seven-valent pneumococcal conjugate vaccine, rates of resistance initially declined because resistance was highest among vaccine strains. Resistance, however, has increased with the emergence of drug-resistant replacement strains. The most prevalent replacement strain (serotype 19A) shows an 83 percent rate of TMP-SMX resistance, but others, such as serotypes 35B and 7F, are uniformly susceptible [<a href="#rid18">18</a>]. This combination antibiotic is not recommended for treatment of respiratory infections that may be due to pneumococcus.</p><p class="headingAnchor" id="H1720181033"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common clinical manifestations of pneumococcal infection</strong> – <em>Streptococcus pneumoniae</em> (pneumococcus) is among the most commonly identified bacterial causes of pneumonia, acute rhinosinusitis, acute otitis media, and acute exacerbations of chronic obstructive pulmonary disease. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Penicillin resistance</strong> – Pneumococci, which used to be broadly antibiotic susceptible, have acquired genetic material that encoded resistance to penicillin and other commonly used antibiotics. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluoroquinolone resistance</strong> – In the United States, approximately 1 to 2 percent of <em>S. pneumoniae</em> isolates are resistant to <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a>, <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a>, or <a class="drug drug_general" data-topicid="8760" href="/d/drug information/8760.html" rel="external">gemifloxacin</a>. Resistance rates are higher in United States nursing homes and in other areas of the world where fluoroquinolones are often used. (See <a class="local">'Prevalence of resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tetracycline</strong><strong> resistance</strong> – In the United States, approximately 20 percent of pneumococcal isolates are resistant to <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> and <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a> and a slightly higher percentage are resistant to <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a>. This resistance rate is substantially higher among penicillin-resistant than among penicillin-susceptible strains. There is substantial variation worldwide, with the rate of tetracycline resistance ranging from 6 percent in Canada to 25 to 40 percent in many other countries. (See <a class="local">'Prevalence of resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trimethoprim-sulfamethoxazole</strong><strong> resistance</strong> – Approximately one-third of all pneumococcal strains in the United States are resistant to <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, with regional variation ranging from 25 percent in the Northeast to 45 percent in the Southeast. In many other countries, rates of resistance are higher, approaching 80 percent in some Southeast Asian countries. (See <a class="local">'Activity and prevalence of resistance'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Musher DM, Abers MS, Bartlett JG. Evolving Understanding of the Causes of Pneumonia in Adults, With Special Attention to the Role of Pneumococcus. Clin Infect Dis 2017; 65:1736.</a></li><li><a class="nounderline abstract_t">Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013; :CD000422.</a></li><li class="breakAll">US Food and Drug Administration. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm500143.htm (Accessed on May 26, 2016).</li><li><a class="nounderline abstract_t">Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200:e45.</a></li><li><a class="nounderline abstract_t">Dever LL, Shashikumar K, Johanson WG Jr. Antibiotics in the treatment of acute exacerbations of chronic bronchitis. Expert Opin Investig Drugs 2002; 11:911.</a></li><li><a class="nounderline abstract_t">Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg 2015; 152:S1.</a></li><li><a class="nounderline abstract_t">Appelbaum PC, Bhamjee A, Scragg JN, et al. Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet 1977; 2:995.</a></li><li><a class="nounderline abstract_t">Jacobs MR, Koornhof HJ, Robins-Browne RM, et al. Emergence of multiply resistant pneumococci. N Engl J Med 1978; 299:735.</a></li><li><a class="nounderline abstract_t">Zhanel GG, Palatnick L, Nichol KA, et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003; 47:1867.</a></li><li><a class="nounderline abstract_t">Thomson KS, Chartrand SA, Sanders CC, Block SL. Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae. Antimicrob Agents Chemother 1997; 41:478.</a></li><li><a class="nounderline abstract_t">Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'. J Antimicrob Chemother 1999; 43 Suppl B:1.</a></li><li><a class="nounderline abstract_t">Fukuda H, Hiramatsu K. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43:410.</a></li><li><a class="nounderline abstract_t">Pestova E, Millichap JJ, Siddiqui F, et al. Non-PmrA-mediated multidrug resistance in Streptococcus pneumoniae. J Antimicrob Chemother 2002; 49:553.</a></li><li><a class="nounderline abstract_t">Smith HJ, Nichol KA, Hoban DJ, Zhanel GG. Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims. J Antimicrob Chemother 2002; 49:893.</a></li><li><a class="nounderline abstract_t">Brueggemann AB, Coffman SL, Rhomberg P, et al. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob Agents Chemother 2002; 46:680.</a></li><li><a class="nounderline abstract_t">Jorgensen JH, Weigel LM, Swenson JM, et al. Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 2000; 44:2962.</a></li><li><a class="nounderline abstract_t">Jones RN, Jacobs MR, Sader HS. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. Int J Antimicrob Agents 2010; 36:197.</a></li><li><a class="nounderline abstract_t">Jacobs MR, Good CE, Windau AR, et al. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 2010; 54:2716.</a></li><li><a class="nounderline abstract_t">Kaur R, Pham M, Yu KOA, Pichichero ME. Rising Pneumococcal Antibiotic Resistance in the Post-13-Valent Pneumococcal Conjugate Vaccine Era in Pediatric Isolates From a Primary Care Setting. Clin Infect Dis 2021; 72:797.</a></li><li><a class="nounderline abstract_t">Kupronis BA, Richards CL, Whitney CG, Active Bacterial Core Surveillance Team. Invasive pneumococcal disease in older adults residing in long-term care facilities and in the community. J Am Geriatr Soc 2003; 51:1520.</a></li><li><a class="nounderline abstract_t">Pletz MW, van der Linden M, von Baum H, et al. Low prevalence of fluoroquinolone resistant strains and resistance precursor strains in Streptococcus pneumoniae from patients with community-acquired pneumonia despite high fluoroquinolone usage. Int J Med Microbiol 2011; 301:53.</a></li><li><a class="nounderline abstract_t">Patel SN, McGeer A, Melano R, et al. Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Antimicrob Agents Chemother 2011; 55:3703.</a></li><li><a class="nounderline abstract_t">Golden AR, Baxter MR, Davidson RJ, et al. Comparison of antimicrobial resistance patterns in Streptococcus pneumoniae from respiratory and blood cultures in Canadian hospitals from 2007-16. J Antimicrob Chemother 2019; 74:iv39.</a></li><li><a class="nounderline abstract_t">Scheld WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 2003; 9:1.</a></li><li><a class="nounderline abstract_t">Pankuch GA, Bozdogan B, Nagai K, et al. Incidence, epidemiology, and characteristics of quinolone-nonsusceptible Streptococcus pneumoniae in Croatia. Antimicrob Agents Chemother 2002; 46:2671.</a></li><li><a class="nounderline abstract_t">Ho PL, Yung RW, Tsang DN, et al. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J Antimicrob Chemother 2001; 48:659.</a></li><li><a class="nounderline abstract_t">Wang H, Chen M, Xu Y, et al. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010. Int J Antimicrob Agents 2011; 38:376.</a></li><li><a class="nounderline abstract_t">Ceyssens PJ, Van Bambeke F, Mattheus W, et al. Molecular Analysis of Rising Fluoroquinolone Resistance in Belgian Non-Invasive Streptococcus pneumoniae Isolates (1995-2014). PLoS One 2016; 11:e0154816.</a></li><li><a class="nounderline abstract_t">Ho PL, Tse WS, Tsang KW, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis 2001; 32:701.</a></li><li><a class="nounderline abstract_t">Jones RN, Wilson ML, Weinstein MP, et al. Contemporary potencies of minocycline and tetracycline HCL tested against Gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria. Diagn Microbiol Infect Dis 2013; 75:402.</a></li><li class="breakAll">Centers for Disease Control and Prevention. 2019. Active Bacterial Core Surveillance Report, Emerging
Infections Program Network, Streptococcus pneumoniae, 2019. https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2019.pdf (Accessed on February 04, 2022).</li><li><a class="nounderline abstract_t">Hoban DJ, Bouchillon SK, Johnson BM, et al. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 2005; 52:215.</a></li><li><a class="nounderline abstract_t">Ragnar Norrby S. Atypical pneumonia in the Nordic countries: aetiology and clinical results of a trial comparing fleroxacin and doxycycline. Nordic Atypical Pneumonia Study Group. J Antimicrob Chemother 1997; 39:499.</a></li><li><a class="nounderline abstract_t">Mokabberi R, Haftbaradaran A, Ravakhah K. Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia. J Clin Pharm Ther 2010; 35:195.</a></li><li><a class="nounderline abstract_t">Choi SH, Cesar A, Snow TAC, et al. Efficacy of Doxycycline for Mild-to-Moderate Community-Acquired Pneumonia in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clin Infect Dis 2023; 76:683.</a></li><li><a class="nounderline abstract_t">Nelson ML, Levy SB. Reversal of tetracycline resistance mediated by different bacterial tetracycline resistance determinants by an inhibitor of the Tet(B) antiport protein. Antimicrob Agents Chemother 1999; 43:1719.</a></li><li><a class="nounderline abstract_t">Steigbigel NH, Reed CW, Finland M. Susceptibility of common pathogenic bacteria to seven tetracycline antibiotics in vitro. Am J Med Sci 1968; 255:179.</a></li><li><a class="nounderline abstract_t">Schaedler RW, Choppin PW, Zabriskie JB. PNEUMONIA CAUSED BY TETRACYCLINE-RESISTANT PNEUMOCOCCI. N Engl J Med 1964; 270:127.</a></li><li><a class="nounderline abstract_t">Holt R, Evans TN, Newman RL. Tetracycline-resistant pneumococci. Lancet 1969; 2:545.</a></li><li><a class="nounderline abstract_t">Kahlmeter G, Kamme C. Tetracycline-resistant group A streptococci and pneumococci. Scand J Infect Dis 1972; 4:193.</a></li><li><a class="nounderline abstract_t">Tetracycline resistance in pneumococci and group A streptococci. Report of an ad-hoc study group on antibiotic resistance. Br Med J 1977; 1:131.</a></li><li><a class="nounderline abstract_t">Hitchings GH. Mechanism of action of trimethoprim-sulfamethoxazole. I. J Infect Dis 1973; 128:Suppl:433.</a></li><li><a class="nounderline abstract_t">Burchall JJ. Mechanism of action of trimethoprim-sulfamethoxazole. II. J Infect Dis 1973; 128:Suppl: 437.</a></li><li><a class="nounderline abstract_t">Simberkoff MS, Lukaszewski M, Cross A, et al. Antibiotic-resistant isolates of Streptococcus pneumoniae from clinical specimens: a cluster of serotype 19A organisms in Brooklyn, New York. J Infect Dis 1986; 153:78.</a></li><li><a class="nounderline abstract_t">Henderson FW, Gilligan PH, Wait K, Goff DA. Nasopharyngeal carriage of antibiotic-resistant pneumococci by children in group day care. J Infect Dis 1988; 157:256.</a></li><li><a class="nounderline abstract_t">Reeves RR, Musher DM. Antibiotic-resistant pneumococcus in a hemophiliac with AIDS. Hosp Pract 1991; 26:81.</a></li><li><a class="nounderline abstract_t">Doern GV, Richter SS, Miller A, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis 2005; 41:139.</a></li><li><a class="nounderline abstract_t">Thornsberry C, Sahm DF, Kelly LJ, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin Infect Dis 2002; 34 Suppl 1:S4.</a></li><li><a class="nounderline abstract_t">Vanderkooi OG, Low DE, Green K, et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40:1288.</a></li></ol></div><div id="topicVersionRevision">Topic 7028 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29028977" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Evolving Understanding of the Causes of Pneumonia in Adults, With Special Attention to the Role of Pneumococcus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23440780" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Vaccines for preventing pneumococcal infection in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23440780" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Vaccines for preventing pneumococcal infection in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31573350" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12084002" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Antibiotics in the treatment of acute exacerbations of chronic bronchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25832968" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical practice guideline (update): adult sinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/72950" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Streptococcus pneumoniae resistant to penicillin and chloramphenicol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29219" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Emergence of multiply resistant pneumococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12760860" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9021213" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10382869" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9925547" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Primary targets of fluoroquinolones in Streptococcus pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11864959" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Non-PmrA-mediated multidrug resistance in Streptococcus pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12039880" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11850248" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11036007" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20558045" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20308374" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32067037" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Rising Pneumococcal Antibiotic Resistance in the Post-13-Valent Pneumococcal Conjugate Vaccine Era in Pediatric Isolates From a Primary Care Setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14687379" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Invasive pneumococcal disease in older adults residing in long-term care facilities and in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20692869" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Low prevalence of fluoroquinolone resistant strains and resistance precursor strains in Streptococcus pneumoniae from patients with community-acquired pneumonia despite high fluoroquinolone usage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21628545" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31505644" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Comparison of antimicrobial resistance patterns in Streptococcus pneumoniae from respiratory and blood cultures in Canadian hospitals from 2007-16.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12533274" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Maintaining fluoroquinolone class efficacy: review of influencing factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12121954" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Incidence, epidemiology, and characteristics of quinolone-nonsusceptible Streptococcus pneumoniae in Croatia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11679555" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21880469" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27227336" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Molecular Analysis of Rising Fluoroquinolone Resistance in Belgian Non-Invasive Streptococcus pneumoniae Isolates (1995-2014).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11229837" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23514756" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Contemporary potencies of minocycline and tetracycline HCL tested against Gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23514756" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Contemporary potencies of minocycline and tetracycline HCL tested against Gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16105567" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9145823" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Atypical pneumonia in the Nordic countries: aetiology and clinical results of a trial comparing fleroxacin and doxycycline. Nordic Atypical Pneumonia Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20456738" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35903011" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Efficacy of Doxycycline for Mild-to-Moderate Community-Acquired Pneumonia in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10390229" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Reversal of tetracycline resistance mediated by different bacterial tetracycline resistance determinants by an inhibitor of the Tet(B) antiport protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4384524" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Susceptibility of common pathogenic bacteria to seven tetracycline antibiotics in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14067010" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : PNEUMONIA CAUSED BY TETRACYCLINE-RESISTANT PNEUMOCOCCI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4184859" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Tetracycline-resistant pneumococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4404850" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Tetracycline-resistant group A streptococci and pneumococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12851" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Tetracycline resistance in pneumococci and group A streptococci. Report of an ad-hoc study group on antibiotic resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4758044" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Mechanism of action of trimethoprim-sulfamethoxazole. I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4585969" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Mechanism of action of trimethoprim-sulfamethoxazole. II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3941289" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Antibiotic-resistant isolates of Streptococcus pneumoniae from clinical specimens: a cluster of serotype 19A organisms in Brooklyn, New York.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3257247" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Nasopharyngeal carriage of antibiotic-resistant pneumococci by children in group day care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Antibiotic-resistant pneumococcus in a hemophiliac with AIDS</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15983908" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11810606" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15825031" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Predicting antimicrobial resistance in invasive pneumococcal infections.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
